Dr. Michael T. Lotze is Professor of Surgery and Bioengineering; Vice Chair of Research within the Department of Surgery; Asst. Vice Chancellor in the six schools of the Health Sciences at Pitt; and Director of Strategic Partnerships within the University of Pittsburgh Cancer Institute as well as the Catalyst Program within the recently funded Clinical and Translational Research Institute. He has worked in the field of Immunology and clinical medicine for over 35 years and believes that a fundamental understanding of cancer biology and immunology is essential to making progress in Oncology.
Dr. Lotze received his MD and B. Med. Sciences from Northwestern University within the Honors Program in Medical Education. He is the co-inventor of 10 patents in dendritic cell vaccines and antigen discovery and serves as associate editor of the Journal of Immunotherapy. He has over 500 publications in peer reviewed journals and book chapters and has edited several texts including three editions of Current Cancer Therapy [with John Kirkwood], the Surgical Treatment of Advanced Cancer [with Joshua Rubin], and Cellular Immunology and the Immunotherapy of Cancer [with Olivera J. Finn]. He developed and edited the 4th Edition of the Cytokine Handbook , the 1st edition of Measuring Immunity , and both editions of Dendritic Cells [1998, 2002], with Dr. Angus Thomson, as well as Cytokines and Cancer  with Michael Caligiuri. His research focuses on the role of necrotic cell death and how it modifies immunity and the biology of inflammation and cancer as well as cellular immunotherapy using cytokines, NK cells, and DCs. His academic career included surgical training at the University of Rochester and fellowships at both the M.D. Anderson Institute and the National Cancer Institute. He was Senior Investigator in the Surgery Branch of the NCI from 1982-1990 and founding director and Chief of the Division of Surgical Oncology at Pitt from 1990-2000. He also helped found its training program in an SSO approved surgical oncology program. Until 2001 he served as Vice-President for Discovery Research in Inflammation and Oncology at SmithKline Beecham and Vice President of High Throughput Biology within Discovery Research in GlaxoSmithKline.
Dr. Lotze is past President of the International Society of Biologic Therapy of Cancer and currently heads up the Federation of Clinical Immunology Societies Centers of Excellence, which is located at 49 sites world-wide.
Dr. Michael T. Lotze
Phone: (412) 623-6790